Hypertrophic heart disease is a leading health problem in Western countries. Here we identified the small EF hand domain-containing protein Ca 2+ and integrin-binding protein-1 (CIB1) in a screen for previously unknown regulators of cardiomyocyte hypertrophy. Yeast two-hybrid screening for CIB1-interacting partners identified a related EF hand domain-containing protein, calcineurin B, the regulatory subunit of the prohypertrophic protein phosphatase calcineurin. CIB1 localizes primarily to the sarcolemma in mouse and human myocardium, where it anchors calcineurin to control its activation in coordination with the L-type Ca 2+ channel. CIB1 protein amounts and membrane association were enhanced in cardiac pathological hypertrophy, but not in physiological hypertrophy. Consistent with these observations, Cib1-deleted mice showed a marked reduction in myocardial hypertrophy, fibrosis, cardiac dysfunction and calcineurin-nuclear factor of activated T cells (NFAT) activity after pressure overload, whereas the degree of physiologic hypertrophy after swimming exercise was not altered. Transgenic mice with inducible and cardiac-specific overexpression of CIB1 showed enhanced cardiac hypertrophy in response to pressure overload or calcineurin signaling. Moreover, mice lacking Ppp3cb (encoding calcineurin A, b isozyme) showed no enhancement in cardiac hypertrophy associated with CIB1 overexpression. Thus, CIB1 functions as a previously undescribed regulator of cardiac hypertrophy through its ability to regulate the association of calcineurin with the sarcolemma and its activation.
a r t i c l e s Heart failure is a serious disease with an 8-year mortality rate between 70% and 80% 1 . One of the major risk factors for developing heart failure is preexisting cardiac hypertrophy resulting from pathologic stimuli such as long-standing hypertension or myocardial infarction 2 . The intracellular signaling pathways involved in the regulation of myocardial growth have been studied in great detail over the past decade 3 . One major prohypertrophic signaling pathway involves the serine-threonine protein phosphatase calcineurin, which is directly activated by Ca 2+ -calmodulin binding when intracellular Ca 2+ levels rise. Activated calcineurin directly binds and dephosphorylates NFAT family transcription factors, causing nuclear translocation and activation of hypertrophic gene expression 4 . Calcineurin is a heterodimer of a 58-to 64-kDa catalytic subunit, calcineurin A (CnA), and a 19-kDa regulatory subunit, calcineurin B (CnB) 4 . Calcineurin can localize to the plasma membrane of cardiac myocytes (also referred to as the sarcolemma) and membrane invaginations called T tubules, which overlie the cytoskeletal Z discs [5] [6] [7] [8] . Calcineurin can also associate with membrane phospholipids through its regulatory subunit CnB 9 . However, it remains uncertain how calcineurin is regulated by Ca 2+ in a contracting cell such as a cardiac myocyte, given the dynamic range of Ca 2+ fluctuations that occur throughout the cytosol to mediate contraction. Partial localization to defined membrane Ca 2+ microdomains might be one mechanism for controlling calcineurin activation. Indeed, calcineurin was recently shown to directly bind the L-type Ca 2+ channel within the sarcolemma, potentially receiving a direct source of Ca 2+ for activation 10 .
In this study, we identified CIB1 (also called calmyrin) as a previously unrecognized regulator of calcineurin-NFAT signaling and cardiac hypertrophy. CIB1 is widely expressed in various human and mouse tissues, with particularly high expression in the heart [11] [12] [13] . CIB1 is a 22-kDa protein containing four EF hand domains, although only the third and fourth C-terminal EF hands functionally bind Ca 2+ at physiologic concentrations 14 . CIB1 can be myristoylated at its N-terminus to mediate plasma membrane localization in multiple cell types [13] [14] [15] . CIB1 can also interact with multiple signaling proteins that reside near the plasma membrane, such as integrin α IIb β 3 , focal adhesion kinase, the small GTPase Rac3, p21-activated kinase and sphingosine kinase 1 (refs. [15] [16] [17] [18] [19] . Although Cib1 −/− mice are viable, they show a defect in spermatogenesis leading to sterility in males, as well as a defect in angiogenesis after ischemia 20, 21 . Here we determined that the extent of calcineurin activation in cardiomyocytes, and the ensuing hypertrophic response, is dependent on sarcolemmal targeting of calcineurin by CIB1.
RESULTS

Characterization of myocardial CIB1 expression
To identify new regulators of cardiomyocyte growth, we performed mRNA array screens for genes that were induced by GATA4 overexpression in cultured neonatal rat cardiomyocytes (data not shown), which causes cell hypertrophy. This screening identified CIB1 as a candidate regulator of cardiomyocyte hypertrophy. Western and northern blotting confirmed that hypertrophy induced by a GATA4-encoding recombinant adenovirus (AdGATA4) strongly induced CIB1 expression in neonatal cardiomyocytes compared with infection with a control adenovirus encoding β-galactosidase (Adβgal) ( Fig. 1a and Supplementary Fig. 1a ). Analysis of heart CIB1 expression in mice in vivo by western blotting and immunohistochemistry revealed high levels at embryonic day 16 (E16), at birth and 1 week after birth, with a progressive reduction in expression with aging ( Fig. 1b,c and Supplementary  Fig. 1b) . Notably, the localization of CIB1 within cardiac myocytes shifted from a diffuse cytoplasmic pattern before birth to the sarcolemma in the adult heart ( Fig. 1c) .
Given the induction of CIB1 expression by GATA4 in neonatal cardiomyocytes, we hypothesized that CIB1 expression might also be induced in the adult heart by prohypertrophic stimuli. Indeed, myocardial CIB1 mRNA and protein levels were upregulated by twofold after 2 weeks of pressure overload stimulation by transverse aortic constriction (TAC) compared to sham-operated control mice (Fig. 1d,e and Supplementary Fig. 1c ). Immunohistochemistry revealed enhanced membrane localization of the protein after 2 weeks of pressure overload but no effects on expression or membrane localization in hearts from mice with physiologic hypertrophy due to swimming exercise ( Fig. 1e,f) . We also detected CIB1 at the sarcolemma in histological sections from control human hearts, and, consistent with our observations in hypertrophied mouse hearts, we observed more CIB1 at the sarcolemma in sections from hypertrophic human hearts than in control hearts ( Fig. 1g ).
CIB1 deficiency inhibits pathological cardiac growth
The increase in CIB1 protein expression and membrane localization during hypertrophic growth suggested a potential functional role for CIB1 in this process. To test this hypothesis, we subjected heterozygous and homozygous Cib1 gene-targeted mice to 2 weeks of TAC: these mice showed reduced or absent CIB1 protein in the heart, respectively ( Fig. 2a) . Notably, myocardial growth was reduced in a dose-dependent manner in Cib1-heterozygous and Cib1-null mice compared with strain-matched wild-type (WT) control mice ( Fig. 2b) . Exposure to pressure overload was similar, as the pressure gradient across the aortic constriction was not statistically different among the three groups of mice subjected to TAC ( Supplementary  Fig. 2a ). Evaluation of cardiomyocyte cross-sectional areas in histological sections after TAC also revealed inhibition in growth in Cib1 −/− compared with WT mice (Fig. 2c) . Consistent with these data, hearts from Cib1 −/− mice showed less induction of the hypertrophic marker genes atrial natriuretic factor (ANF) and β-myosin heavy chain (β-MHC) after 2 weeks of TAC compared with WT controls ( Fig. 2d and Supplementary Fig. 2b ). Finally, a r t i c l e s because CIB1 was previously shown to be necessary for ischemic angiogenesis outside the heart 21 , we also assessed capillary density. Capillary density normalized to myocyte content was not different between Cib1 −/− and WT hearts after sham or TAC operation ( Supplementary Fig. 2c,e ). However, when not normalized to myocyte content, Cib1 −/− hearts had more capillaries per microscopic viewing field in histological sections compared to WT hearts after TAC, which could be a protective adaptation in these hearts ( Supplementary Fig. 2d,e ).
To determine the impact of CIB1 deficiency on heart failure predisposition, we subjected WT and Cib1 −/− mice to 6 weeks of pressure overload and determined cardiac function at weekly intervals thereafter by echocardiography. Whereas the initial pressure gradient imposed by TAC was not different between WT and Cib1 −/− mice ( Supplementary Fig. 3a ), WT mice showed significantly greater reductions in fractional shortening compared with Cib1 −/− mice 3 to 6 weeks after TAC ( Fig. 2e , P < 0.05). Histological analysis with Masson's trichrome staining and subsequent quantification of the fibrotic area (blue staining) revealed significantly more fibrosis in the hearts of WT mice compared to Cib1 −/− mice at 6 weeks after TAC ( Fig. 2f,g , P < 0.05). This result was corroborated by measuring hydroxyproline content in the heart as an indicator of collagen content ( Supplementary Fig. 3b ). Taken together, these results indicate that CIB1 is involved in regulating the pathologic hypertrophic response of the myocardium to pressure overload stimulation, as well as secondary decompensation. In support of the idea that CIB1 preferentially regulates pathological cardiac hypertrophy compared to physiological hypertrophy, loss of this protein did not attenuate cardiac hypertrophy in response to swimming exercise ( Fig. 2h) .
Because CIB1 expression was induced in pathological cardiac hypertrophy, it was of interest to determine whether it could also regulate the hypertrophic response in cultured neonatal cardiac myocytes. To this end, we lowered endogenous CIB1 expression with a specific siRNA ( Supplementary Fig. 3c ). CIB1-specific siRNA transfection significantly reduced the increase in cell growth and hypertrophic marker gene expression (ANF and B-type natriuretic peptide) induced by the prohypertrophic α1-adrenergic agonist phenylephrine ( Supplementary Fig. 3d-f , P < 0.05).
CIB1 interacts with CnB
Our finding that Cib1 −/− mice were partially protected from pathologic hypertrophy suggested a functional role for CIB1 in regulating intracellular signaling, especially because CIB1 has already been shown to interact with specific signaling effectors [15] [16] [17] [18] [19] . We first investigated the activation status of a wide array of signaling pathways in response to CIB1 overexpression or deletion. However, we observed no alterations in the activation of extracellular signal-regulated kinases (ERK1/2), p38 mitogen-activated protein kinase, c-Jun N-terminal kinase (JNK), Akt, glycogen synthase kinase-3β (GSK-3β) or nuclear factor-κB ( Supplementary Fig. 4 ). Given these negative results, we turned to a yeast two-hybrid assay to identify CIB1-interacting proteins and determine how it might be signaling in cardiac myocytes. Using this approach with a CIB1 'bait' , we obtained three independent cDNA 'preys' encoding CnB. cDNAs encoding both the short and long isoforms of CnB were isolated. Retransformation of yeast cells with the CIB1 bait and CnB preys confirmed an interaction that was similar in intensity to a positive control consisting of a CnA bait with a CnB prey ( Fig. 3a) . We next showed that immunoprecipitation of either CnB or CnA from lysates of cardiac myocytes overexpressing either of these two proteins also pulled down CIB1 (Fig. 3b,c) . Moreover, in the absence of protein overexpression, immunoprecipitation of endogenous CIB1 pulled down endogenous CnB from lysates of WT hearts (Fig. 3d) . Because only the short isoform of CnB is expressed in the heart and most other tissues ( Supplementary Fig. 5) , it was used for all subsequent experiments and simply referred to as CnB. We incubated in vitro-synthesized and 35 S-methionine-labeled CnB with full-length or truncated versions of a GST-CIB1 fusion protein or with GST alone. GST alone, GST-CIB1 1-55, GST-CIB1 1-82 or GST-CIB1 1-108 did not interact with CnB, whereas full-length GST-CIB1 and GST-CIB1 1-132 did (Fig. 3e) . Therefore, the region corresponding to the functional C-terminal EF hand domains of CIB1 is responsible for its interaction with CnB.
CIB1 mediates the association of CnB with the sarcolemma CIB1 is a myristoylated protein, suggesting that CIB1 might regulate calcineurin membrane localization and activity. To test this hypothesis, we performed CnB immunostaining in frozen sections from WT and Cib1 −/− hearts after sham and TAC surgery. We observed and Cib1 −/− hearts after TAC, although there was a trend toward an increase in CnA amounts after TAC in WT hearts (Fig. 4b) .
In agreement with the immunohistochemical results, we found CnB and CnA protein in the plasma membrane fraction of WT but not Cib1 −/− hearts after TAC (Fig. 4c) . The purity of the plasma membrane fraction was shown by the presence of the Na + -K + ATPase and the lack of sarcoplasmic reticulum Ca 2+ ATPase-2 (SERCA2; a marker for sarcoplasmic reticulum) or GAPDH ( Fig. 4c) . Notably, TAC stimulation led to the enrichment of calcineurin with the plasma membrane protein fraction in WT hearts but not Cib1 −/− hearts ( Fig. 4c) . As a control, the Na + -K + ATPase was used as an irrelevant membrane protein that was equally enriched at the plasma membrane after TAC in both WT and Cib1 −/− hearts (Fig. 4c) . The cytosolic and total membrane protein fractions contained equal amounts of CnB in WT and Cib1 −/− hearts, either with or without TAC stimulation ( Fig. 4d) . We used sarcoplasmic reticulum Ca 2+ ATPase-2 (SERCA2), WT All membrane Cytosol Tot.
WT WT WT
CnB
CnA CIB1 Na slightly enhanced levels of CnB at the membrane in hearts of WT mice subjected to TAC compared with sham hearts, but did not detect CnB at the membrane in Cib1 −/− hearts at baseline or after TAC (Fig. 4a) .
To exclude the possibility that the protein abundance of CnB or CnA was changed in Cib1 −/− hearts, we examined CnA and CnB protein amounts and found that they did not significantly differ between WT a r t i c l e s pan-cadherin and integrin β1 antibodies to show that membrane proteins were enriched in the "all membrane" fraction, whereas glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was enriched in the cytosolic fraction ( Fig. 4d) .
To further characterize the loss of CnB at the sarcolemma in the absence of CIB1, we cultured cardiac myocytes from adult WT and Cib1 −/− mice and performed CnB immunostaining. CnB was localized at the sarcolemma in WT cardiomyocytes but was displaced in Cib1 −/− myocytes (Fig. 4e) . CnB could be retargeted to the membrane of Cib1 −/− adult myocytes by AdCIB1 infection, but not by infection with a mutant version of CIB1 (CIB1Δ) lacking the N-terminal myristoylation site (Fig. 4e) . CIB1Δ was also no longer able to associate with the plasma membrane in infected cultured cardiomyocytes (Fig. 4f) . Collectively, these data suggest that CIB1 is necessary for anchoring calcineurin at the sarcolemma.
CIB1 activates calcineurin-NFAT signaling
Given that CIB1 interacts with calcineurin and is responsible for its sarcolemmal localization, we further hypothesized that CIB1 might directly regulate calcineurin signaling. To measure the impact of CIB1 on calcineurin-NFAT activity, we infected neonatal cardiomyocytes with an NFAT-luciferase reporter adenovirus, with and without co-infection with AdCIB1 (Fig. 5a) . Whereas AdCIB1 alone did not activate the NFAT-luciferase reporter as compared to Adβgal infection, AdCIB1 dramatically enhanced NFAT activity induced by the prohypertrophic α1-adrenergic agonist phenylephrine (Fig. 5a) . This synergistic increase in NFAT activity was blocked by overexpression of the calcineurin inhibitor Cain, consistent with the idea that the increase in NFAT activity is due to a direct effect of CIB1 on calcineurin, rather than on NFAT. However, overexpression of CIB1Δ, which cannot localize to the membrane, was not nearly as effective as CIB1 in augmenting phenylephrine-induced NFAT-luciferase reporter activity, suggesting that CIB1 enhances calcineurin-NFAT activity through a membrane localization-dependent mechanism (Fig. 5b) . As a control, recombinant CIB1 protein did not directly induce the phosphatase activity of recombinant CnA in an in vitro assay (Fig. 5c) , also supporting the hypothesis that CIB1 augments calcineurin activity through membrane targeting.
To further investigate the mechanism whereby CIB1 regulates calcineurin and the hypertrophic response, we examined NFAT activation in cultured cardiomyocytes with reduced CIB1 expression. CIB1 siRNA transfection significantly reduced NFAT activation in phenylephrinestimulated myocytes as compared to transfection of a control siRNA ( Fig. 5d , P < 0.05). The effectiveness of the siRNA-mediated knockdown of CIB1 in this assay is shown in Supplementary Figure 3c . We also generated Cib1 −/− mice containing the NFAT luciferase reportertransgene and found that 1 week of TAC led to a significant elevation in NFAT-luciferase activity in Cib1 +/+ but not Cib1 −/− mice ( Fig. 5e , P < 0.05). These data indicate that CIB1 is a key activator of calcineurin-NFAT signaling in hypertrophied cardiomyocytes.
CIB1 is similar in structure to CnB in that both are small EF handcontaining, Ca 2+ -binding proteins, suggesting the possibility that CIB1 might be able to substitute for CnB in regulating CnA activity. However, CIB1 overexpression in Ppp3r1 (encoding CnB1)-deleted mouse embryonic fibroblasts was unable to stabilize endogenous CnA protein levels as assessed by western blotting for CnA, suggesting that CIB1 is not functionally equivalent to CnB (Fig. 5f) . Calcineurin has been shown to associate with the L-type Ca 2+ channel in cardiac a r t i c l e s myocytes 10 , which resides in the sarcolemma where it might also be part of the CIB1 complex. Indeed, we observed that CIB1 interacted with the α1C subunit of the L-type Ca 2+ channel in TAC-stimulated hearts, but not in hearts at baseline (Fig. 5g) . Mapping of this interaction showed that the region immediately N-terminal to the EF hand domains of CIB1 (amino acids 82-108) are necessary for the interaction with α1C, as determined by a GST pull-down assay from cardiomyocyte protein extracts (Fig. 5h) . These data raise the possibility that CIB1 might be a primary mechanism for recruiting calcineurin to the L-type Ca 2+ channel for activation. Indeed, treatment of cardiomyocytes with verapamil (an L-type Ca 2+ channel inhibitor), was equally potent in reducing phenylephrine-stimulated NFAT-luciferase activity as CIB1 siRNA, but verapamil treatment did not further lower activity when administered together with CIB1 siRNA. These results suggest that CIB1 and the L-type Ca 2+ channel might coordinately regulate calcineurin (Fig. 5i) .
Characterization of CIB1-transgenic mice
Myocardial CIB1 expression is upregulated twofold during pressure overload (Fig. 1d) . We modeled this increase in CIB1 abundance by generating transgenic mice with tetracycline-regulated and cardiacspecific expression of this protein under control of the α-MHC promoter 22 (Fig. 6a ). This inducible system uses a driver transgene expressing the tetracycline activator protein (tTA) in the presence of the CIB1 responder transgene, so that CIB1 protein expression is induced in double-transgenic mice in the absence of tetracycline or doxycycline (Fig. 6b) . For all experiments, we discontinued doxycycline treatment at 1 month of age, resulting in 2.5-fold overexpression of CIB1 in the heart in double-transgenic mice of two lines, designated 26.6 and 27.5. However, in the absence of doxycycline treatment during development, the hearts of 3-month-old line 27.5 double-transgenic mice showed tenfold CIB1 overexpression compared to controls (Fig. 6b) . Neither 2.5-nor tenfold overexpression of CIB1 affected cardiac function or hypertrophy at baseline ( Supplementary Table 1 ).
For both transgenic lines (using the regimen of doxycycline withdrawal to result in a 2.5-fold overexpression of CIB1), we observed a significantly enhanced cardiac hypertrophic response after TAC compared with control mice (nontransgenic mice and single α-MHC-tTA-transgenic mice, Fig. 6c , P < 0.05). To determine whether this enhanced hypertrophic response was associated with an increase in calcineurin-NFAT signaling, we generated CIB1-inducible transgenic mice that also carried the NFAT-luciferase reporter transgene. In these mice, CIB1 overexpression resulted in a significant increase in NFAT activity after TAC ( Fig. 6d , P < 0.05). Similarly, CIB1 overexpression in cultured cardiomyocytes by adenoviral gene transfer significantly enhanced phenylephrineinduced cardiomyocyte hypertrophy ( Fig. 6e , P < 0.05). CIB1 overexpression in transgenic hearts had no effect on components of other signaling pathways that we tested, including mitogenactivated protein kinase, Akt-GSK-3β, and nuclear factor-κB ( Supplementary Fig. 6 ).
We also crossed CIB1 inducible transgenic mice with transgenic mice that have cardiac-specific expression of a truncated, activated form of calcineurin A (ΔCnA). ΔCnA-transgenic mice are known to display cardiac hypertrophy characterized by twofold larger hearts 23 . Hypertrophy in ΔCnA hearts was associated with increased myocardial expression of the CnB protein (Fig. 6f) . As our results indicate that CnB is a direct target of CIB1, we next tested whether overexpression of CIB1 could further enhance the hypertrophic response in ΔCnA-transgenic mice. Indeed, this was the case (Fig. 6g) , indicating that calcineurin activation can be augmented by CIB1 in vivo. We also investigated whether CnB is required for the prohypertrophic effects of CIB1 by crossing CIB1 double-transgenic mice into the Ppp3cb −/− genetic background. We previously demonstrated that Ppp3cb −/− mice are partially protected from pressure overload hypertrophy 24 . Notably, CIB1 overexpression did not result in increased cardiac hypertrophy in mice containing the Ppp3cb −/− mutation compared to strain-matched backcrossed Ppp3cb +/+ mice (Fig. 6h) , suggesting that CIB1 acts upstream of calcineurin. Ppp3cb a r t i c l e s DISCUSSION Here we identify CIB1 as a unique regulator of pathological cardiac hypertrophy and calcineurin-NFAT signaling in cardiac myocytes. CIB1 shares substantial sequence and structural homology with CnB, calmodulin and neuronal calcium sensory proteins such as KChip, frequenin and neurocalcin. On the basis of structural criteria, CIB1 and the homologous proteins CIB2, CIB3 and CIB4 form a distinct subfamily of small EF hand domain proteins, suggesting unique functions for this protein subfamily 14 . CIB2 is highly expressed in skeletal muscle, but not in the heart, and is localized to the sarcolemma, myotendinous and neuromuscular junctions 25 . Similarly, we observed CIB1 at the sarcolemma in both adult mouse and human heart, and this membrane localization was enhanced during pathologic hypertrophy, although we also observed CIB1 protein localized diffusely throughout the cardiomyocyte cytoplasm before birth. It has previously been shown that CIB1 localizes to the plasma membrane in fibroblasts, human venous endothelial cells and cultured platelets 15 . In HeLa cells, overexpressed CIB1 was detected in the nucleus, at the plasma membrane and in the endoplasmic reticulum, but CIB1 mutants defective in myristoylation were displaced from the membrane and were found to have a diffuse cytoplasmic and nuclear localization 13, 26 .
In mice, myocardial CIB1 expression is relatively high before birth and gradually becomes downregulated toward adulthood. However, CIB1 is re-induced in the adult heart during pathological hypertrophy, similar to other cardiac 'fetal program' genes associated with hypertrophy, such as those encoding ANF, B-type natriuretic peptide, skeletal α-actin and β-MHC 3, 27 . We demonstrated that upregulation of CIB1 is functionally important during pressure overload, as Cib1 −/− mice have a significant loss in the hypertrophic response after 2 weeks of TAC, whereas transgenic mice overexpressing CIB1 showed augmented hypertrophy. Chronic exposure to increased hemodynamic load on the heart triggers adaptive and maladaptive signaling pathways in producing hypertrophy. Whereas inhibition of the maladaptive pathways is a desirable goal of antihypertrophic therapies and strategies toward preventing heart failure, simultaneous inhibition of adaptive signaling pathways would be detrimental 27 . Examples of the latter include deletion of the genes encoding melusin or Akt1, which results in reduced cardiac hypertrophy but also the development of heart failure in mice 28, 29 . In contrast, Cib1 deletion preserves cardiac function and capillary density and diminishes myocardial fibrosis during chronic pressure overload, much like deletion of Ppp3cb 24 , and is therefore a preferable target to inhibit maladaptive signaling. In support of this notion, Cib1 deletion did not affect exercise-induced cardiac hypertrophy, which is associated with adaptive intracellular signaling.
The identification of CnB as a CIB1-interacting protein in the yeast two-hybrid screen suggested a mechanism underlying the observed alterations in cardiac hypertrophy associated with CIB1 overexpression or deficiency. CnB is the exclusive and obligate binding partner of the CnA catalytic subunit, and neither protein is appreciably stable without expression of the other 30 . Calcineurin is a prohypertrophic signaling mediator that functions primarily through NFAT transcription factors in maladaptive programming of cardiac growth 4, 31, 32 . Overexpression of CIB1 facilitated calcineurin-NFAT activation, whereas downregulation of CIB1 impaired calcineurin-NFAT signaling in cultured cardiac myocytes and in the hearts of transgenic mice.
Because CIB1 is localized at the sarcolemma, we hypothesized that it could target calcineurin to this region of the cell to allow sensing of local Ca 2+ concentrations that might be different from total intracellular Ca 2+ concentrations involved in regulating myocyte contraction. Calcineurin association with the plasma membrane has been previously reported 5, 33 . Calcineurin can also interact with the L-type Ca 2+ channel at the plasma membrane in the heart, where it activates the channel to increase Ca 2+ influx 10 . Because calcineurin is activated by Ca 2+ , possibly in response to Ca 2+ flux through the L-type channel itself, a feed-forward loop was proposed in activating a pool of calcineurin 10 . We show here that CIB1 interacts with the L-type Ca 2+ channel and enables calcineurin to translocate to the sarcolemma, possibly to facilitate calcineurin's L-type Ca 2+ channel interaction. Indeed, CnB is unable to localize to the sarcolemma in Cib1 −/− cardiomyocytes, and a non-membrane-targeting version of CIB1 was not nearly as effective in enhancing NFAT activation after stimulation as full-length CIB1, nor did it allow CnB to associate with the cell membrane. Moreover, in primary rat cardiomyocytes, in which the L-type Ca 2+ channel was inhibited (by verapamil treatment), the effect of CIB1 downregulation on calcineurin-NFAT activation was abolished. Previous work has also revealed the importance of calcineurin's membrane localization; for example, the CnB subunit of calcineurin can interact with phospholipids, enhancing calcineurin's activity in vitro 9, 34 . Furthermore, recent data suggest that the membrane-anchoring and PDZ domain-containing protein PICK1 (protein interacting with C kinase) interacts with CnB and is necessary for calcineurin-NFAT activation 35 . Although the mechanisms regulating calcineurin activation are complex, our data clearly show that CIB1 is required for permitting activation of calcineurin during maladaptive cardiac hypertrophy, suggesting a new strategy for treating hypertrophic heart disease through inhibition of CIB1 or its interaction with calcineurin.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
